<p> Blockade of the cytokine IL-3 is a promising novel strategy for patients with rheumatoid arthritis. In contrast to existing therapies an IL-3 blocker could prevent disease exacerbation during early phases of the disease. Such product could substitute TNFα-blockers and open new markets for disease prevention <p> We offer the opportunity for development of IL-3 antagonists for treatment of patients with rheumatoid arthritis. The next steps of product development are clearly defined and include in vitro characterization of antibodies in various functional assays, additional in vivo studies in mouse arthritis models, humanization of a suitable monoclonal antibody and the preparation for a phase I clinical trial. <p>
email@example.com | TechnologieAllianz e.V.
New Lithium Salts of Pentafluorophenylamide Anions as Electrolytes in Lithium Ionic Batteries
18.04.2017 | TechnologieAllianz e.V.
Gratings on glass surfaces
28.03.2017 | TechnologieAllianz e.V.
19.09.2017 | Event News
12.09.2017 | Event News
06.09.2017 | Event News
21.09.2017 | Physics and Astronomy
21.09.2017 | Life Sciences
21.09.2017 | Health and Medicine